Remdesivir for the Treatment of Covid-19 — Final Report
By J. Beigel, Kay M. Tomashek, L. Dodd, Aneesh K. Mehta, Barry S. Zingman, Andre C. Kalil, E. Hohmann, H. Y. Chu, Anne F. Luetkemeyer, S. Kline and 30 more. New England Journal of Medicine, 2020
5,537 citations recorded by the source corpus.
Abstract Background Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious. Methods We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. Results A total of 1062 patients underwent randomization (with 541 assigned to remdesivir and 521 to placebo). Those who received remdesivir had a median recovery time of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI, 1.12 to 1.49; P<0.001, by a log-rank test). In an analysis that used a proportional-odds model with an eight-category ordinal scale, the patients who received remdesivir were found to be more likely than those who received placebo to have clinical improvement at day 15 (odds ratio, 1.5; 95% CI, 1.2 to 1.9, after adjustment for actual disease severity). The Kaplan–Meier estimates of mortality were 6.7% with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). Serious adverse events were reported in 131 of the 532 patients who received remdesivir (24.6%) and in 163 of the 516 patients who received placebo (31.6%). Conclusions Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACTT-1 ClinicalTrials.gov number, NCT04280705.)
Subfields: Infectious Diseases, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/322b45c8d67f37127a60153166a8532bd0a51fd3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
In Molecular Biology
- Alessandro Sette
- Bjoern Peters
- Alba Grifoni
- A. Ward
- David Golan
- Michael Proschan
- J. Esko
- Cameron Martino
Citations in the corpus
- SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2 (2020, background): “Currently, only one antiviral agent, Remdesivir, has been approved for adult COVID-19 patients (Beigel et al., 2020) and vaccines may be 12-18 months away.”
- SARS-CoV-2 viral load is associated with increased disease severity and mortality (2020, background): “An example is the reported clinical benefit of remdesivir 33 despite the lack of evidence that remdesivir significantly reduces respiratory tract viral loads 34 .”
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 (2020, background): “The authors’ affiliations are as follows: the University of Nebraska Medical Center, Omaha (A.C.K., L.L.); University of Texas Health San Antonio, University Health, and the South Texas Veterans Health Care System, San Antonio (T.F.P., P.O.P., B.S.T.), UT Southwestern Medical Center, Parkland Health”
- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. (2021, methodology): “When the mixed-model repeated-measure analysis was used, it included: (1) treatment group, (2) stratification factor of duration since symptom onset to randomization (≤8 days vs >8 days), (3) baseline value in the model, (4) visit day (ie, 1, 3, 7, and 11), and (5) the treatment × visit interaction ”
- Dexamethasone in Hospitalized Patients with Covid-19 (2021, neutral): “Unknown 190 (9) 399 (9) 123 (8) 327 (8) 139 (14)”